Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant Staphylococci

Journal of Antibiotics

Volumn 68, Issue 4, 2015, Pages 259-266

  Mohammad, Haroon ^a   Mayhoub, Abdelrahman S ^b   Cushman, Mark ^c   Seleem, Mohamed N ^a  

^a PURDUE UNIVERSITY   (United States)

^b AL AZHAR UNIVERSITY   (Egypt)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; THIAZOLE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANT STAPHYLOCOCCUS; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; BIOFILM; DRUG EFFECTS; DRUG POTENTIATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SYNTHESIS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GLYCOPEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; THIAZOLES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84928781973     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.142     Document Type: Article

References (41)

1. CDC. Antibiotic Resistance Threats in the United States, 2013, 1-114 (Centers for Disease Control and Prevention, Atlanta, GA, USA, 2013).
2. Moran, G. J. et al. Methicillin-resistant S. aureus infections among patients in the emergency department. New Engl. J. Med. 355, 666-674 (2006).
3. Wang, R. et al. Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. J. Clin. Invest. 121, 238-248 (2011).
4. Davies D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2003; 2: 114-122.
5. Mah, T. F. & O'Toole, G. A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9, 34-39 (2001).
6. Chambers, H. F. Community-associated MRSA-resistance and virulence converge. New Engl. J. Med. 352, 1485-1487 (2005).
7. Moran, G. J., Amii, R. N., Abrahamian, F. M. & Talan, D. A. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis. 11, 928-930 (2005).
8. Hiramatsu, K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1, 147-155 (2001).
9. Hays, S. J. et al. Substituted 2-benzothiazolamine as sodium flux inhibitors - quantitative structure-activity-relationships and anticonvulsant activity. J. Pharm. Sci. 83, 1425-1432 (1994).
10. Das, J. et al. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56 (lck) inhibitors. Bioorg. Med. Chem. Lett. 13, 2587-2590 (2003).
11. Hutchinson, I., Bradshaw, T. D., Matthews, C. S., Stevens, M. F. & Westwell, A. D. Antitumour benzothiazoles. Part 20: 3'-cyano and 3'-alkynyl-substituted 2-(4'-aminophenyl) benzothiazoles as new potent and selective analogues. Bioorg. Med. Chem. Lett. 13, 471-474 (2003).
12. Paget, C. J., Kisner, K., Stone, R. L. & DeLong, D. C. Heterocyclic substituted ureas. II. Immunosuppressive and antiviral activity of benzothiazole- and benzoxazoleureas. J. Med. Chem. 12, 1016-1018 (1969).
13. Darwish, E. S., Fattah, A. M. A., Attaby, F. A. & Al-Shayea, O. N. Synthesis and antimicrobial evaluation of some novel thiazole, pyridone, pyrazole, chromene, hydrazone derivatives bearing a biologically active sulfonamide moiety. Int. J. Mol. Sci. 15, 1237-1254 (2014).
14. Desai, N. C., Bhatt, N., Somani, H. & Trivedi, A. Synthesis, antimicrobial and cytotoxic activities of some novel thiazole clubbed 1, 3, 4-oxadiazoles. Eur. J. Med. Chem. 67, 54-59 (2013).
15. Sadek, B., Al-Tabakha, M. M. & Fahelelbom, K. M. S. Antimicrobial prospect of newly synthesized 1, 3-thiazole derivatives. Molecules 16, 9386-9396 (2011).
16. Mohammad, H. et al. Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant staphylococcus aureus. J. Med. Chem. 57, 1609-1615 (2014).
17. Mayhoub, A. S. et al. An investigation of phenylthiazole antiflaviviral agents. Bioorg. Med. Chem. 19, 3845-3854 (2011).
18. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7 (Wayne, PA, USA, 2011).
19. Messick, C. R., Rodvold, K. A. & Pendland, S. L. Modified time-kill assay against multidrug-resistant Enterococcus faecium with novel antimicrobial combinations. J. Antimicrob. Chemoth. 44, 831-834 (1999).
20. Baldoni, D., Haschke, M., Rajacic, Z., Zimmerli, W. & Trampuz, A. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents. Chemother. 53, 1142-1148 (2009).
21. Nagai, K. et al. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents. Chemother. 44, 2740-2746 (2000).
22. Orhan, G., Bayram, A., Zer, Y. & Balci, I. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J. Clin. Microbiol. 43, 140-143 (2005).
23. Furlani, R. E., Yeagley, A. A. & Melander, C. A flexible approach to 1, 4-disubstituted 2-aminoimidazoles that inhibit and disperse biofilms and potentiate the effects of B-lactams against multi-drug resistant bacteria. Eur. J. Med. Chem. 2013; 62: 59-70.
24. O'Toole, G. A. Microtiter dish biofilm formation assay. J. Vis. Exp. 2011; 2437.
25. Mohamed, M. F., Hamed, M. I., Panitch, A. & Seleem, M. N. Targeting methicillinresistant staphylococcus aureus with short salt-resistant synthetic peptides. Antimicrob. Agents Chemother. 58, 4113-4122 (2014).
26. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. NCCLS Approved Standard M7-A9 (NCCLS: Wayne, PA, USA, 2012).
27. Alder, J. & Eisenstein, B. The advantage of bactericidal drugs in the treatment of infection. Curr. Infect. Dis. Rep. 6, 251-253 (2004).
28. Pankey, G. A. & Sabath, L. D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38, 864-870 (2004).
29. McDougal, L. K. et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41, 5113-5120 (2003).
30. Deresinski, S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 49, 1072-1079 (2009).
31. Finberg, R. W. et al. The importance of bactericidal drugs: future directions in infectious disease. Clin. Infect. Dis. 39, 1314-1320 (2004).
32. Kosowska-Shick, K. et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53, 4217-4224 (2009).
33. Nguyen, H. M. & Graber, C. J. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J. Antimicrob. Chemoth. 65, 24-36 (2010).
34. Dumitrescu, O. et al. Effect of antibiotics, alone and in combination, on Panton- Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin. Microbiol. Infect. 14, 384-388 (2008).
35. Stevens, D. L. et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195, 202-211 (2007).
36. Leonidou, L. & Gogos, C. A. Catheter-related bloodstream infections: catheter management according to pathogen. Int. J. Antimicrob. Agents 36, S26-S32 (2010).
37. Vuong, C. & Otto, M. Staphylococcus epidermidis infections. Microbes Infect. 4, 481-489 (2002).
38. More, P. G., Karale, N. N., Lawand, A. S., Narang, N. & Patil, R. H. Synthesis and antibiofilm activity of thiazole Schiff bases. Med. Chem. Res. 23, 790-799 (2014).
39. Rane, R. A., Sahu, N. U. & Shah, C. P. Synthesis and antibiofilm activity of marine natural product-based 4-thiazolidinones derivatives. Bioorg. Med. Chem. Lett. 22, 7131-7134 (2012).
40. Kwong, A. D., Kauffman, R. S., Hurter, P. & Mueller, P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 29, 993-1003 (2011).
41. Allegrini P. & Brunoldi E. Process for the preparation of a viral protease inhibitor in amorphous form. Google Patents WO2013153055 A1 (2013).